ข่าวประชาสัมพันธ์ hypoglycaemia

Ryzodeg(R) Offers a Simpler Solution With Once-Daily Dosing and Reduced Risk of Nocturnal Hypoglycaemia vs Insulin Glargine U100 Plus Insulin Aspart

When treated with once-daily Ryzodeg(R), people with type 2 diabetes achieved similar blood sugar control with half the number of daily injections, significantly lower total daily insulin dose and significantly reduced risk of nocturnal hypoglycaemia in the Step by Step trial compared with once-daily insulin glargine U100 plus once-daily insulin aspart after 26 weeks. Ryzodeg(R) is a combination of insulin degludec and insulin aspart (IDegAsp) in one pen for the treatment of people with type 2

02 ตุลาคม 2561 16:59 น.

People With Diabetes May Achieve Improved Glycaemic Control With Tresiba(R) Versus Glargine U100, Without an Increase in Hypoglycaemia

According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control (HbA1c) with... ต.ค. 61

Ryzodeg(R) Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

In people with type 2 diabetes who fast during Ramadan, Ryzodeg(R) (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe... ธ.ค. 60

Tresiba(R) Reduces Hypoglycaemia Regardless of Blood Sugar Level

People with either type 1 or type 2 diabetes treated with Tresiba(R) had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets.[1]... ธ.ค. 60

Switching to Tresiba(R) Benefits People with Diabetes Irrespective of Blood Sugar Levels in a Real-world Setting

- Switching to Tresiba(R) reduced the rate of hypoglycaemia by 67% in people with controlled blood sugar levels - In people with diabetes whose blood sugar was too high, switching to... ธ.ค. 60

Tresiba(R) Trial Shows that People with Type 2 Diabetes who Avoid Severe Hypoglycaemia have a Reduced Risk of Death

Symposium: S33 Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia... ก.ย. 60

Tresiba(R) (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100

This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 87-LB and 90... มิ.ย. 59

Ryzodeg(R) Delivers Significantly Lower Rates of Hypoglycaemia and Nocturnal Hypoglycaemia in a Broad Range of Type 2 Diabetes Patients

- This material is intended for global medical media only. - This material is not approved for Canadian journalists or Canadian audiences. - For journalistic... ธ.ค. 58

Lilly and Boehringer Ingelheim Present Health Outcomes Data for Investigational Novel Basal Insulin Analogue

Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue,... ต.ค. 55

Type 2 Diabetes Patients with Long-Standing Disease Achieved Glycaemic Control When BYETTA(R) (exenatide) Injection Was Added to Insulin Glargine

Study Presented at ADA 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from the first double... มิ.ย. 53